Fidelity Investments
MACK

Fidelity Investments’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Fidelity Investments’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,263
Closed -$122K – 5755
2024
Q1 		$122K Sell
8,263
-654
-7% -$9.19K ﹤0.01% 3201
2023
Q4 		$120K Sell
8,917
-409
-4% -$5.17K ﹤0.01% 3145
2023
Q3 		$115K Buy
9,326
+8,990
+2,676% +$109K ﹤0.01% 3059
2023
Q2 		$4.13K Buy
336
+166
+98% +$2.08K ﹤0.01% 4415
2023
Q1 		$2.09K Buy
+170
New +$2K ﹤0.01% 4619
2022
Q4 		– Sell
-1
Closed – – 5715
2022
Q3 		$0 Buy
+1
New +$5 ﹤0.01% 5657
2021
Q1 		– Sell
-1
Closed – – 4798
2020
Q4 		$0 Hold
1
– – ﹤0.01% 4483
2020
Q3 		$0 Hold
1
– – ﹤0.01% 4189
2020
Q2 		$0 Sell
1
-8
-89% -$27 ﹤0.01% 4459
2020
Q1 		$0 Hold
9
– – ﹤0.01% 4556
2019
Q4 		$0 Sell
9
-5
-36% -$20 ﹤0.01% 4525
2019
Q3 		$0 Sell
14
-33
-70% -$165 ﹤0.01% 4466
2019
Q2 		$0 Sell
47
-65
-58% -$308 ﹤0.01% 4426
2019
Q1 		$1K Sell
112
-76
-40% -$349 ﹤0.01% 3561
2018
Q4 		$1K Sell
188
-786
-81% -$2.73K ﹤0.01% 3479
2018
Q3 		$4K Sell
974
-61,395
-98% -$259K ﹤0.01% 3325
2018
Q2 		$241K Sell
62,369
-1,990,320
-97% -$13.2M ﹤0.01% 2567
2018
Q1 		$13M Buy
2,052,689
+23,635
+1% +$196K ﹤0.01% 1876
2017
Q4 		$16.4M Buy
2,029,054
+18,260
+0.9% +$170K ﹤0.01% 1796
2017
Q3 		$23M Sell
2,010,794
-181,728
-8% -$1.91M ﹤0.01% 1649
2017
Q2 		$21.4M Sell
2,192,522
-262,995
-11% -$5.37M ﹤0.01% 1656
2017
Q1 		$59.5M Sell
2,455,517
-15,611
-0.6% -$391K 0.01% 1224
2016
Q4 		$79.3M Buy
2,471,128
+7,152
+0.3% +$305K 0.01% 1109
2016
Q3 		$123M Buy
2,463,976
+28,896
+1% +$1.2M 0.02% 888
2016
Q2 		$103M Buy
2,435,080
+222,385
+10% +$12.1M 0.01% 954
2016
Q1 		$146M Buy
2,212,695
+9,274
+0.4% +$484K 0.02% 808
2015
Q4 		$137M Buy
2,203,421
+79,215
+4% +$5.57M 0.02% 829
2015
Q3 		$142M Buy
2,124,206
+26,592
+1% +$2.17M 0.02% 797
2015
Q2 		$204M Buy
2,097,614
+46,290
+2% +$4.4M 0.03% 683
2015
Q1 		$192M Buy
2,051,324
+32,643
+2% +$2.78M 0.02% 712
2014
Q4 		$179M Buy
2,018,681
+24,719
+1% +$1.8M 0.02% 730
2014
Q3 		$138M Buy
1,993,962
+22,543
+1% +$1.2M 0.02% 824
2014
Q2 		$113M Buy
1,971,419
+2,924
+0.1% +$148K 0.02% 941
2014
Q1 		$78.1M Buy
1,968,495
+17,240
+0.9% +$738K 0.01% 1111
2013
Q4 		$82M Sell
1,951,255
-30,668
-2% -$889K 0.01% 1071
2013
Q3 		$59.3M Sell
1,981,923
-43,448
-2% -$1.52M 0.01% 1196
2013
Q2 		$107M Buy
+2,025,371
New +$88.8M 0.02% 886

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity Investments's MACK Position: Q2 2024 in Review

Fidelity Investments sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 8,263 shares — an estimated $122K sold.

Fidelity Investments first reported a position in MACK in Q2 2013 and held it in 37 quarters. The position peaked at $204M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Fidelity Investments reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Fidelity Investments sold 8,263 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $122K.
  • Fidelity Investments first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 37 quarters.
  • Fidelity Investments's Merrimack Pharmaceuticals, Inc. position peaked at $204M in Q2 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.